2025 Global Anti-Infective Vaccines Market Revenue Opportunities Report
Description
The 2025 Global Anti-Infective Vaccines Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global anti-infective vaccines market are GlaxoSmithKline (GSK), Sanofi, Merck & Co., and Pfizer Inc. GSK leads with a 20-25% market share, offering a broad vaccine portfolio including Arexvy for RSV and Shingrix for herpes zoster, focusing on global growth despite some sales challenges. Sanofi holds 15-20%, specializing in vaccines against infectious diseases like meningitis, with a robust R&D pipeline and worldwide reach in over 170 countries. Merck & Co., owning 12-15% of the market, recently obtained FDA approval for Capvaxive, a broad pneumococcal vaccine competing directly with Pfizer’s Prevnar 20. Pfizer controls 10-12%, deeply entrenched in pneumococcal vaccine leadership with Prevnar 20 and maintains a powerful global distribution network and innovation pipeline focused on expanding vaccine coverage.
These companies are key players at The World stage, addressing pressing global health needs. Pfizer's mRNA vaccine Comirnaty marked a significant breakthrough in COVID-19 immunization and continues to expand in infant use. Sanofi is a top manufacturer of flu vaccines and is advancing regulatory approvals for new COVID-19 vaccines, partnering with other firms for innovative candidates. Merck & Co. leverages its diverse vaccine offerings and recent approvals to maintain competitive strength against Pfizer. Moderna, an emerging major vaccine manufacturer, is distinguished by its mRNA technology, developing next-generation COVID-19 boosters and vaccines against influenza and RSV, contributing to global pandemic preparedness despite being smaller in market share. Collectively, these corporations drive substantial innovation and distribution in anti-infective vaccines worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Infective Vaccines Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global anti-infective vaccines market are GlaxoSmithKline (GSK), Sanofi, Merck & Co., and Pfizer Inc. GSK leads with a 20-25% market share, offering a broad vaccine portfolio including Arexvy for RSV and Shingrix for herpes zoster, focusing on global growth despite some sales challenges. Sanofi holds 15-20%, specializing in vaccines against infectious diseases like meningitis, with a robust R&D pipeline and worldwide reach in over 170 countries. Merck & Co., owning 12-15% of the market, recently obtained FDA approval for Capvaxive, a broad pneumococcal vaccine competing directly with Pfizer’s Prevnar 20. Pfizer controls 10-12%, deeply entrenched in pneumococcal vaccine leadership with Prevnar 20 and maintains a powerful global distribution network and innovation pipeline focused on expanding vaccine coverage.
These companies are key players at The World stage, addressing pressing global health needs. Pfizer's mRNA vaccine Comirnaty marked a significant breakthrough in COVID-19 immunization and continues to expand in infant use. Sanofi is a top manufacturer of flu vaccines and is advancing regulatory approvals for new COVID-19 vaccines, partnering with other firms for innovative candidates. Merck & Co. leverages its diverse vaccine offerings and recent approvals to maintain competitive strength against Pfizer. Moderna, an emerging major vaccine manufacturer, is distinguished by its mRNA technology, developing next-generation COVID-19 boosters and vaccines against influenza and RSV, contributing to global pandemic preparedness despite being smaller in market share. Collectively, these corporations drive substantial innovation and distribution in anti-infective vaccines worldwide.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
